Tilavist ophthalmic solution

Tilavist, known generically as Nedocromil sodium, is a mast-cell stabilizer used primarily to treat allergic conjunctivitis. It was originally developed as a specialized treatment for optical allergies to prevent the release of inflammatory substances.

The brand has undergone several changes in ownership through the consolidation of the global pharmaceutical industry. Originally associated with companies like Fisons and later Rhone-Poulenc Rorer, the brand eventually became part of the Sanofi portfolio. Today, while it is still manufactured and distributed in various global markets, its availability and local ownership may vary by region. Sanofi, headquartered in France, remains the primary ultimate owner of the brand's legacy and global rights. Production typically occurs in specialized pharmaceutical facilities located in Europe and other international logistics hubs.